Study evaluates 9-minute flow-immunosensor for canine CRP
Bottom line
A new study in the Journal of Veterinary Diagnostic Investigation evaluated a flow-type immunosensor system for measuring canine C-reactive protein, or CRP, and found it tracked closely with a comparative particle-enhanced turbidimetric immunoassay while cutting assay time to 9 minutes. The authors, Akihisa Hata, Norio Tateishi, and Hideki Toita, reported within-run imprecision of 8.2% and 6.4% at roughly 39 and 115 mg/L, between-run imprecision of 9.9% and 6.5%, a lower limit of quantification of 4.0 mg/L, and confirmed linearity from 4.0 to 300 mg/L. In 43 canine heparinized plasma samples, the new system showed strong agreement with the reference method, and it remained robust in the presence of common interferents including hemoglobin, lipids, and bilirubin. (researchgate.net)
Why it matters: CRP is already widely used in dogs as a nonspecific marker of inflammation and for monitoring treatment response, including after surgery and during infectious or inflammatory disease. For veterinary teams, the practical appeal here is speed plus benchside potential: a 9-minute assay with acceptable analytical performance could make CRP more useful during same-visit triage, rechecks, and treatment monitoring. But the broader literature also shows a recurring issue in canine CRP testing: assays can correlate well without being interchangeable, so practices may still need method-specific reference intervals and caution when trending results across platforms. (researchgate.net)
What to watch: The next question is whether this platform moves beyond analytical validation into broader clinical adoption, external validation, and assay standardization work across CRP systems. (jstage.jst.go.jp)
Key facts
- Study
- Performance evaluation of a canine C-reactive protein flow-immunosensor measurement system for clinical application
- Journal
- Journal of Veterinary Diagnostic Investigation
- Analyte
- Canine C-reactive protein (CRP)
- Method
- Flow-type immunosensor system
- Comparison method
- Particle-enhanced turbidimetric immunoassay
- Assay time
- 9 minutes
- Sample size
- 43 canine heparinized plasma samples
- Lower limit of quantification
- 4.0 mg/L
- Linearity
- 4.0 to 300 mg/L
A newly published study in the Journal of Veterinary Diagnostic Investigation suggests a faster flow-immunosensor option for canine C-reactive protein testing may be ready for clinical use. The paper evaluated a flow-type immunosensor, or FIS, system for canine CRP and found strong agreement with a comparative particle-enhanced turbidimetric immunoassay, while reducing measurement time to 9 minutes. (researchgate.net)
That matters because canine CRP has become a familiar tool in small animal practice, especially as a nonspecific marker of inflammation and a way to monitor response to treatment. Prior studies and reviews have described CRP as clinically useful in dogs because it rises quickly with inflammatory stimuli and falls relatively quickly during recovery, making it attractive for serial monitoring rather than one-time diagnosis alone. At the same time, the veterinary diagnostics market has accumulated a mix of ELISA, immunoturbidimetric, dry chemistry, fluorescent, and point-of-care approaches, each with different calibration systems and performance characteristics. (pmc.ncbi.nlm.nih.gov)
The new paper builds on earlier work from the same research line. In a 2022 development study, investigators reported that an earlier FIS-based canine CRP device achieved repeatability below 2.4%, intermediate precision below 4.4%, a lower limit of quantification of 3.9 mg/L, and linearity up to 465 mg/L, with a correlation coefficient of 0.9809 versus an automated analyzer method in 39 plasma samples. The new 2026 clinical-application paper appears to shift the focus from proof of concept to practical deployment, specifically by shortening runtime to 9 minutes and testing robustness against common analytical interferents. (researchgate.net)
According to the study summary, the updated system delivered within-run imprecision of 8.2% and 6.4% at about 39 and 115 mg/L, and between-run imprecision of 9.9% and 6.5% across 20 measurement days. The lower limit of quantification was 4.0 mg/L, and linearity was confirmed from 4.0 to 300 mg/L. In 43 canine heparinized plasma samples, the regression equation versus the comparative method was y = 0.979x + 0.592, with R² = 0.974. The authors also reported robustness against hemoglobin, lipids, and bilirubin, which are common preanalytic or analytic trouble points in routine practice. (researchgate.net)
The broader literature offers a useful reality check. Multiple canine CRP assays have shown acceptable analytical performance, including IDEXX Catalyst, Gentian, VetChroma, and other point-of-care formats, but cross-platform comparability remains a persistent limitation. A 2025 advance publication from the Journal of Veterinary Medical Science, which included Akihisa Hata among its authors, found strong correlations among three CRP assay systems used in Japan but concluded they were not interchangeable because of systematic error. The authors said those findings support system-specific reference ranges and decision thresholds, and suggest a common calibration agent may be needed for standardization. (pubmed.ncbi.nlm.nih.gov)
No independent expert commentary or company press release was readily available in the search results tied directly to this new paper. Still, the industry direction is clear from recent publications: developers are trying to bring canine CRP testing closer to the point of care without giving up analytical reliability. Reviews of canine CRP testing have also emphasized that assay choice matters, particularly when clinicians use CRP to follow trends over time or to help guide decisions such as response to therapy. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is less about a brand-new biomarker than about workflow. If a 9-minute FIS assay can be run reliably in clinic settings and hold up under real-world sample interference, it could make CRP more actionable during the visit, not after it. That could support faster inflammatory assessment, better monitoring after surgery or hospitalization, and more consistent communication with pet parents about whether a dog appears to be improving. But practices should be careful not to overread the result: CRP remains a nonspecific marker, and the literature continues to show that values from different assay platforms should not automatically be trended as if they were equivalent. (researchgate.net)
What to watch: The next steps are likely external validation in broader clinical populations, publication of full decision thresholds for this platform, and any movement toward assay harmonization so clinics can compare results more confidently across instruments and laboratories. (jstage.jst.go.jp)